: Chronic migraine is a disease with a high burden on patients from both a working and quality of life point of view. The pathophysiology of this subtype of migraine is due to several factors, such as medication overuse. Nevertheless, the detrimental recurring of headache attacks with central and peripheral sensitization plays a central role and explains some additional symptoms complained about by these patients even in the interictal phase. OnabotulinumtoxinA is a therapy indicated for chronic migraine since it has proven to reduce peripheral sensitization, showing even efficacy on central symptoms. The aim of this narrative review is to present the current evidence regarding the effect of OnabotulinumtoxinA on sensitization and interictal symptoms.
Alonge, P., Brighina, F., Maccora, S., Pilati, L., Di Marco, S., Ventimiglia, D., et al. (2024). Beyond Pain: The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine [10.3390/toxins16050203].
Beyond Pain: The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine
Alonge, PaoloPrimo
Writing – Original Draft Preparation
;Brighina, Filippo
Secondo
Conceptualization
;Maccora, SimonaMembro del Collaboration Group
;Pilati, LauraMembro del Collaboration Group
;Ventimiglia, DavideMembro del Collaboration Group
;Maggio, BrunaMembro del Collaboration Group
;Camarda, CeciliaMembro del Collaboration Group
;Torrente, AngeloUltimo
Writing – Review & Editing
2024-04-23
Abstract
: Chronic migraine is a disease with a high burden on patients from both a working and quality of life point of view. The pathophysiology of this subtype of migraine is due to several factors, such as medication overuse. Nevertheless, the detrimental recurring of headache attacks with central and peripheral sensitization plays a central role and explains some additional symptoms complained about by these patients even in the interictal phase. OnabotulinumtoxinA is a therapy indicated for chronic migraine since it has proven to reduce peripheral sensitization, showing even efficacy on central symptoms. The aim of this narrative review is to present the current evidence regarding the effect of OnabotulinumtoxinA on sensitization and interictal symptoms.File | Dimensione | Formato | |
---|---|---|---|
2024 Beyond Pain The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
925.81 kB
Formato
Adobe PDF
|
925.81 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.